Pharma major Venus Remedies has secured its first marketing authorisation in Switzerland from Swiss drug authority 'Swissmedic' for its oncology drug 'Gemcitabine'.
The marketing approval for Gemcitabine will help the company further strengthen its oncology portfolio and improve its presence in this space, Venus Remedies said in a statement here today.
The Panchkula-based company plans to launch the drug early next quarter and the product will be launched in Switzerland by Swiss Pharma GmbH, with which Venus has a marketing tie-up, it said.
"The launch of this product will add to the company's top line and bottom line in the coming quarters," it said.
Venus Remedies has already received more than 20 marketing approvals for Gemcitabine injection from various countries. The product is being sold in the UK, Poland and Germany.
Gemcitabine is an anti-cancer drug used for the treatment of a variety of cancerous conditions, including the cancer of the lungs, pancreas, bladder and breast.
